{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T05:15:17Z","timestamp":1794719717907,"version":"4.9.1"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1097\/md.0000000000002486","type":"journal-article","created":{"date-parts":[[2016,1,13]],"date-time":"2016-01-13T17:17:40Z","timestamp":1452705460000},"page":"e2486","source":"Crossref","is-referenced-by-count":18,"title":["Combination of White Blood Cell Count at Presentation With Molecular Response at 3 Months Better Predicts Deep Molecular Responses to Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients"],"prefix":"10.1097","volume":"95","author":[{"given":"Ya-Zhen","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Yun","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Hu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Rong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-65-20210826","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"IRIS Investigators. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukaemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"R2-65-20210826","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukaemia","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"R3-65-20210826","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"key":"R5-65-20210826","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s11427-015-4926-0","article-title":"Fighting against hematological malignancy in China: from unique system to global impact","volume":"58","author":"Lv","year":"2015","journal-title":"Sci China Life Sci"},{"key":"R6-65-20210826","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/asheducation-2014.1.234","article-title":"Goals for chronic myeloid leukemia TK inhibitor treatment: how little disease is too much?","volume":"2014","author":"Mauro","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R7-65-20210826","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1158\/1078-0432.CCR-13-1988","article-title":"Deep molecular response in chronic myeloid leukemia: the new goal of therapy?","volume":"20","author":"Mahon","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R8-65-20210826","doi-asserted-by":"crossref","first-page":"S227","DOI":"10.1007\/s00277-015-2327-x","article-title":"Response-related predictors of survival in CML","volume":"94","author":"Hanfstein","year":"2015","journal-title":"Ann Hematol"},{"key":"R9-65-20210826","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV","volume":"32","author":"Hehlmann","year":"2014","journal-title":"J Clin Oncol"},{"key":"R10-65-20210826","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"R11-65-20210826","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"R12-65-20210826","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"R13-65-20210826","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"R14-65-20210826","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djr292","article-title":"Severe peripheral arterial disease during nilotinib therapy","volume":"103","author":"Le Coutre","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"R15-65-20210826","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2466-11-30","article-title":"Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?","volume":"11","author":"Hennigs","year":"2011","journal-title":"BMC Pulm Med"},{"key":"R16-65-20210826","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"key":"R17-65-20210826","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"key":"R18-65-20210826","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","article-title":"Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib","volume":"123","author":"Hughes","year":"2014","journal-title":"Blood"},{"key":"R19-65-20210826","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","article-title":"Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML","volume":"121","author":"Branford","year":"2013","journal-title":"Blood"},{"key":"R21-65-20210826","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"R22-65-20210826","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"R23-65-20210826","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"key":"R24-65-20210826","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.leukres.2008.07.015","article-title":"Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels","volume":"33","author":"Forrest","year":"2009","journal-title":"Leuk Res"},{"key":"R25-65-20210826","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.3324\/haematol.2013.085167","article-title":"A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction","volume":"98","author":"Shinohara","year":"2013","journal-title":"Haematologica"},{"key":"R26-65-20210826","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1185\/03007995.2014.991817","article-title":"Treatment patterns and prognostic indicators of response to therapy among patients with chronic myeloid leukemia in Australia, Canada, and South Korea","volume":"31","author":"Whiteley","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"R27-65-20210826","doi-asserted-by":"crossref","first-page":"E135","DOI":"10.1002\/ajh.24022","article-title":"Combination of eutos score and 3-month bcr-abl transcript level identifies a group of good-risk chronic myeloid leukemia patients with favourable response to frontline imatinib therapy","volume":"90","author":"Tiribelli","year":"2015","journal-title":"Am J Hematol"},{"key":"R28-65-20210826","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1182\/blood-2006-01-024729","article-title":"Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)","volume":"109","author":"Schultz","year":"2007","journal-title":"Blood"},{"key":"R29-65-20210826","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/ejh.12130","article-title":"Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease","volume":"91","author":"Hoyos","year":"2013","journal-title":"Eur J Haematol"},{"key":"R30-65-20210826","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1751-553X.2007.00962.x","article-title":"Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response","volume":"30","author":"Qin","year":"2008","journal-title":"Int J Lab Hematol"},{"key":"R31-65-20210826","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.leukres.2013.06.003","article-title":"Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL (IS) or log reduction from the baseline level?","volume":"37","author":"Qin","year":"2013","journal-title":"Leuk Res"},{"key":"R32-65-20210826","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"R34-65-20210826","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood-2010-09-308510","article-title":"Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase","volume":"117","author":"Jiang","year":"2011","journal-title":"Blood"},{"key":"R35-65-20210826","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.clml.2012.12.005","article-title":"The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure","volume":"13","author":"Jabbour","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R36-65-20210826","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1200\/JCO.2011.37.6962","article-title":"European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation","volume":"29","author":"Marin","year":"2011","journal-title":"J Clin Oncol"},{"key":"R37-65-20210826","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1182\/blood-2011-10-388967","article-title":"EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience","volume":"119","author":"Jabbour","year":"2012","journal-title":"Blood"},{"key":"R38-65-20210826","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/cas.12321","article-title":"European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients","volume":"105","author":"Yamamoto","year":"2014","journal-title":"Cancer Sci"},{"key":"R39-65-20210826","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/1097-0142(19880401)61:7<1441::AID-CNCR2820610727>3.0.CO;2-C","article-title":"Characteristics of accelerated disease in chronic myelogenous leukemia","volume":"61","author":"Kantarjian","year":"1988","journal-title":"Cancer"},{"key":"R40-65-20210826","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","article-title":"Australasian Leukaemia and Lymphoma Group. Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600\u200amg\/day of imatinib as initial therapy","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"key":"R41-65-20210826","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/leu.2008.308","article-title":"BCR\/ABL induces chromosomal instability after genotoxic stress and alters the cell death threshold","volume":"23","author":"Dierov","year":"2009","journal-title":"Leukemia"},{"key":"R42-65-20210826","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1007\/s11427-015-4965-6","article-title":"An overview of chronic myeloid leukemia and its animal models","volume":"58","author":"Ma","year":"2015","journal-title":"Sci China Life Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201601120-00065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T14:21:23Z","timestamp":1629987683000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201601120-00065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000002486","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}